Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
Point-of-sale cart
Enterprise seamless mobility
Replacing memory pointers with implicit pointers to be used in compiler-generated debug output
Heterogeneous language data typing without executable regeneration
Engine RPM control device
Large scale data storage system with fault tolerance
Lacrosse head
  Randomly Featured Patents
Process for forming a fine resist pattern
Spark plug
Fluoroelastomer and its cross-linkable composition
Transmission and reception matching method for a cordless communication apparatus and apparatus thereof
Method of making a vertical integrated circuit
IL-8 receptor antagonists
Process for decomposing N-oxide derivatives producing 5-vinyl-2-pyrrolidones
Process and apparatus for dispensing liquids to a remote bathroom fixture
Focused, single strand, optical fiber rotational alignment image-sensing and comparing system
Insulation product and system suitable for use in an aircraft